Big Pharma · Metabolic · United States

AstraZeneca — Metabolic in United States

OncologyRare DiseaseImmunologyCardiometabolic
Commission a AstraZeneca report

AXLRx AstraZeneca intelligence — Metabolic in United States: 1 report covering Metabolic in United States.

All areas NeurologyImmunologyMetabolicOncologyRare Disease
Market: All United States
Market access — United States

Tagrisso dominant in first-line EGFR+ NSCLC; Alexion complement franchise (Ultomiris/Soliris) holds strong specialty access.

AXLRx reports featuring AstraZeneca — Metabolic in United States
MASH
CI
CI Metabolic CI TeamLaunch Lead

US MASH Competitive Intelligence

Rezdiffra and Wegovy now split the noncirrhotic MASH label. This is a Year 0 to Year 1 access and retention fight, not a pre-launch window.

US In-Market Read report →